Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of symptomatic aortic stenosis (AS). However, the benefits of TAVR are mitigated by the occurrence of stroke, which remains a major issue of this procedure, associated with increased mortality and early-reduced quality of life. Indeed, the PARTNER IIA trial reported a 30-day stroke rate of 5.5% after TAVR, confirming that procedure-related neurological events remain a significant concern even in lower-risk patients and with next-generation transcatheter heart valves.